Pluri (PLUR) Non-Current Deffered Revenue (2011 - 2015)
Pluri (PLUR) reported Non-Current Deffered Revenue of $2.4 million for Q3 2015, down 13.77% year-over-year from $2.8 million in Q3 2014, and down 3.85% quarter-over-quarter from $2.5 million in Q2 2015.
Pluri (PLUR) Non-Current Deffered Revenue (2011 - 2015) Analysis & Trends
Pluri (PLUR) has 5 years of Non-Current Deffered Revenue data on file, last reported at $2.4 million in Q3 2015.
- Non-Current Deffered Revenue for Q3 2015 came in at $2.4 million, down 13.77% year-over-year; the trailing twelve-month figure through Sep 2015 was $2.4 million (down 13.77% YoY), and the FY2015 annual result was $2.5 million, down 13.31% from the prior year.
- Non-Current Deffered Revenue retreated to $2.4 million in Q3 2015 per PLUR's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $3.9 million in Q3 2011 and troughed at $3116.0 in Q4 2012.
- A 5-year average of $2.9 million and a median of $3.0 million in 2013 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2012 and 2013: Non-Current Deffered Revenue plunged 99.92% in 2012, then jumped 97332.61% in 2013.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $3.7 million in 2011, then sank by 99.92% to $3116.0 in 2012, then jumped by 97332.61% to $3.0 million in 2013, then declined by 12.48% to $2.7 million in 2014, then decreased by 10.69% to $2.4 million in 2015.
- Business Quant data shows PLUR's Non-Current Deffered Revenue at $2.4 million in Q3 2015, $2.5 million in Q2 2015, and $2.7 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Pluri | 21.85 Mn | 22.34 Mn | 86,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 2.37 Mn |
| Jun 30, 2015 | 2.47 Mn |
| Dec 31, 2014 | 2.66 Mn |
| Sep 30, 2014 | 2.75 Mn |
| Jun 30, 2014 | 2.85 Mn |
| Mar 31, 2014 | 2.94 Mn |
| Dec 31, 2013 | 3.04 Mn |
| Sep 30, 2013 | 3.13 Mn |
| Jun 30, 2013 | 3.23 Mn |
| Mar 31, 2013 | 2.92 Mn |
| Dec 31, 2012 | 3,116.00 |
| Sep 30, 2012 | 3.31 Mn |
| Jun 30, 2012 | 3.51 Mn |
| Mar 31, 2012 | 3.46 Mn |
| Dec 31, 2011 | 3.69 Mn |
| Sep 30, 2011 | 3.92 Mn |